表紙
市場調查報告書
商品編碼
974408

類風濕性關節炎 (RA) - 至2029年的流行病學預測

Rheumatoid Arthritis - Epidemiology Forecast to 2029

出版日期: | 出版商: GlobalData | 英文 46 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

主要8個國家(美國、法國、德國、義大利、西班牙、英國、日本、澳洲) 的類風濕性關節炎 (RA) 和確診的發病數量,預計從2019年的389,747件,增加到2029年的425,455件,以0.92%AGR成長。

本報告提供主要8個國家與的類風濕性關節炎 (RA) 調查分析,危險因素全球趨勢,10年的流行病學預測相關的系統性資訊。

目錄

第1章 目錄

第2章 類風濕性關節炎 (RA) :摘要整理

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢與歷史的趨勢
  • 預測手法
  • RA的流行病學預測
    • RA確診的發病數量
    • RA確診的發病數量:性別
    • RA確診的發病數量:各年齡
    • RA確診的患病人數
    • RA確診的患病人數:性別
    • RA確診的患病人數:各年齡
    • RA確診的患病人數:各重症度
    • RA的總患病人數
    • RA的總患病人數:性別
    • RA的總患病人數:各年齡
    • RA的總患病人數:各重症度
  • 討論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER260-20

Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. The condition manifests itself in multiple joints in the body (Mayo Clinic, 2019; Centers for Disease Control and Prevention, 2020). RA is the result of an immune response in which the body's immune system attacks its own healthy cells, especially the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response (Centers for Disease Control and Prevention, 2020). The disease can lead to premature mortality, disability, and decreased quality of life due to bone erosion and joint deformity (Brooks, 2006; Centers for Disease Control and Prevention, 2020).

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals to build the forecast. GlobalData epidemiologists used sources that confirmed RA cases based on the American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06, in order to ensure a uniform case definition across markets. The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent (total and diagnosed) cases of RA in the 8MM, segmented by age, sex, and severity.

The following data describes epidemiology of RA. In the 8MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of RA from 389,747 cases in 2019 to 425,455 cases in 2029, at an AGR of 0.92% over the forecast period. The diagnosed prevalent cases of RA in the 8MM will increase from 4,605,338 cases in 2019 to 5,093,229 cases in 2029, at an AGR of 1.06% over the forecast period. The total prevalent cases of RA in the 8MM will increase from 6,308,268 cases in 2019 to 6,980,823 cases in 2029, at an AGR of 1.07% over the forecast period. RA is more common in women, and the incidence and prevalence of RA typically increases with advancing age. These trends are reflected in GlobalData's forecast for the diagnosed incident and prevalent (total and diagnosed) cases for the 8MM.

Scope

  • The Rheumatoid Arthritis (RA) Epidemiology Report provides an overview of the risk factors and global trends of IPF in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent cases of RA (total and diagnosed) segmented by sex and age (ages ≥18 years). The prevalent cases of RA (total and diagnosed) are also segmented by severity (mild, moderate, and severe). In addition, the model corresponding to this report includes prevalent cases of RA (total and diagnosed) segmented by comorbidities (depression, cardiovascular disease, cancer, gastrointestinal ulcer, hypertension, hyperlipidemia, obesity, osteoporosis, osteoarthritis, chronic obstructive pulmonary disease, and asthma).
  • The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The Rheumatoid Arthritis Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global RA market.
  • Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RA therapeutics in each of the markets covered.
  • Understand magnitude of RA population by severity at diagnosis.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for RA (2019-2029)
    • 3.5.1 Diagnosed Incident Cases of RA
    • 3.5.2 Sex-Specific Diagnosed Incident Cases of RA
    • 3.5.3 Age-Specific Diagnosed Incident Cases of RA
    • 3.5.4 Diagnosed Prevalent Cases of RA
    • 3.5.5 Sex-Specific Diagnosed Prevalent Cases of RA
    • 3.5.6 Age-Specific Diagnosed Prevalent Cases of RA
    • 3.5.7 Diagnosed Prevalent Cases of RA by Severity
    • 3.5.8 Total Prevalent Cases of RA
    • 3.5.9 Sex-Specific Total Prevalent Cases of RA
    • 3.5.10 Age-Specific Total Prevalent Cases of RA
    • 3.5.11 Total Prevalent Cases of RA by Severity
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - KOLs Interviewed for this Report
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer

List of Tables

List of Tables

  • Table 1: Summary of Updated Data Types
  • Table 2: Risk Factors and Comorbidities for RA

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 2: 8MM, Diagnosed Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 3: 8MM, Diagnosed Incidence of RA (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2019
  • Figure 4: 8MM, Diagnosed Prevalence (%) of RA, Both Sexes, Ages ≥18 Years, 2019
  • Figure 5: 8MM, Total Prevalence (%) of RA, Both Sexes, Ages ≥18 Years, 2019
  • Figure 6: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of RA
  • Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed and Total Prevalent Cases of RA
  • Figure 8: 8MM, Diagnosed Incident Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 9: 8MM, Diagnosed Incident Cases of RA, N, by Sex, Ages ≥18 Years, 2019
  • Figure 10: 8MM, Diagnosed Incident Cases of RA by Age, N, Both Sexes, 2019
  • Figure 11: 8MM, Diagnosed Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 12: 8MM, Diagnosed Prevalent Cases of RA, N, by Sex, Ages ≥18 Years, 2019
  • Figure 13: 8MM, Diagnosed Prevalent Cases of RA by Age, N, Both Sexes, 2019
  • Figure 14: 8MM, Diagnosed Prevalent Cases of RA by Severity, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 15: 8MM, Total Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 16: 8MM, Total Prevalent Cases of RA, N, by Sex, Ages ≥18 Years, 2019
  • Figure 17: 8MM, Total Prevalent Cases of RA by Age, N, Both Sexes, 2019
  • Figure 18: 8MM, Total Prevalent Cases of RA by Severity, N, Both Sexes, Ages ≥18 Years, 2019